2-(2-nitrophenyl)-1H-imidazo<4,5-b>pyridine | 148215-62-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 2-(2-nitrophenyl)-1H-imidazo<4,5-b>pyridine
• 英文别名: 2-(2-nitrophenyl)-1H-imidazo[4,5-b]pyridine
• CAS: 148215-62-7
• 化学式: C₁₂H₈N₄O₂
• 分子量: 240.221
• InChiKey: FWPWJMXDSWDKDK-UHFFFAOYSA-N

物化性质

• 沸点：
  444.3±47.0 °C(Predicted)
• 密度：
  1.50±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  18
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  87.4
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2-(2-nitrophenyl)-1H-imidazo<4,5-b>pyridine 在 palladium on activated charcoal sodium tetrahydroborate 、 4 A molecular sieve 、 氢气 作用下， 以 乙醇 、 溶剂黄146 为溶剂， 25.0 ℃ 、344.73 kPa 条件下， 反应 201.0h， 生成 2-(2-(propylamino)phenyl)-1H-imidazo<4,5-b>pyridine
  参考文献：
  名称：

  咪唑并吡啶抑制环核苷酸磷酸二酯酶：舒马唑和异唑的类似物作为cGMP特异性磷酸二酯酶的抑制剂。

  摘要：

  描述了一系列咪唑并吡啶（包括舒马唑和异唑）对分离的PDE同工酶的合成和磷酸二酯酶（PDE）抑制谱。结果表明，舒马唑和异咪唑都是PDE III的弱抑制剂，它们的正性活性不太可能仅由于PDE III的抑制而引起。出乎意料的是，发现这两种化合物都是cGMP特异性同工酶PDE V的重要抑制剂，并且已经制备了一系列简单的2-取代的苯基咪唑并[4,5-b]吡啶用于研究PDE活性的SAR。已显示这对链长，极性和杂原子连接基团的性质敏感。已经确定了有效的PDE V抑制剂，其中许多也是PDE IV的重要抑制剂。

  DOI：

  10.1021/jm00062a011
• 作为产物：
  描述：

  2,3-二氨基吡啶 生成 2-(2-nitrophenyl)-1H-imidazo<4,5-b>pyridine
  参考文献：
  名称：

  DUBEY P. K.; RATNAM C. V., PROC. INDIAN ACAD. SCI. , 1977, A85, NO 4, 204-209

  摘要：

  DOI：

文献信息

• Sirtuin modulating compounds
  申请人：Nunes J. Joseph

  公开号：US20070037809A1

  公开（公告）日：2007-02-15

  Provided herein are novel sirtuin-modulating compounds and methods of use thereof. The sirtuin-modulating compounds may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders including, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benfit from increased mitochondrial activity. Also provided are compositions comprising a sirtuin-modulating compound in combination with another therapeutic agent.

  本文提供了新型的sirtuin调节化合物及其使用方法。这些sirtuin调节化合物可用于增加细胞寿命，并治疗和/或预防各种疾病和疾病，包括与衰老或应激有关的疾病或疾病，糖尿病，肥胖症，神经退行性疾病，心血管疾病，血液凝块性疾病，炎症，癌症和/或红斑病，以及需要增加线粒体活性的疾病或疾病。还提供了包含sirtuin调节化合物和另一种治疗剂的组合物。
• SIRTUIN MODULATING COMPOUNDS
  申请人：Nunes Joseph J.

  公开号：US20120197013A1

  公开（公告）日：2012-08-02

  Provided herein are novel sirtuin-modulating compounds and methods of use thereof. The sirtuin-modulating compounds may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders including, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity. Also provided are compositions comprising a sirtuin-modulating compound in combination with another therapeutic agent.

  本文提供了一种新颖的调节沉默信息调节因子（sirtuin）的化合物及其使用方法。这些调节sirtuin的化合物可用于延长细胞寿命，并用于治疗和/或预防多种疾病和障碍，包括与衰老或应激有关的疾病或障碍、糖尿病、肥胖症、神经退行性疾病、心血管疾病、血液凝结障碍、炎症、癌症和/或潮红，以及需要增加线粒体活性的疾病或障碍。还提供了包含sirtuin调节化合物与另一种治疗药物组合的组合物。
• Imidazo[2,1-b]thiazole derivatives as sirtuin modulators
  申请人：Sirtris Pharmaceuticals, Inc.

  公开号：EP2388263A1

  公开（公告）日：2011-11-23

  Provided herein are novel sirtuin-modulating compounds and methods of use thereof. The sirtuin-modulating compounds may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders including, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benfit from increased mitochondrial activity. Also provided are compositions comprising a sirtuin-modulating compound in combination with another therapeutic agent.

  本文提供了新型sirtuin调节化合物及其使用方法。sirtuin调节化合物可用于延长细胞寿命，治疗和/或预防多种疾病和失调，包括与衰老或压力、糖尿病、肥胖症、神经退行性疾病、心血管疾病、凝血障碍、炎症、癌症和/或潮红有关的疾病或失调，以及可从线粒体活性增强中获益的疾病或失调。此外，还提供了由sirtuin调节化合物与另一种治疗剂组合而成的组合物。
• Thiazolopyridine derivatives as sirtuin-modulators
  申请人：Sirtris Pharmaceuticals, Inc.

  公开号：EP2468752A1

  公开（公告）日：2012-06-27

  Provided herein are novel sirtuin-modulating compounds (XII) and (XIII). The sirtuin-modulating compounds may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders including, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity. Also provided are compositions comprising a sirtuin-modulating compound in combination with another therapeutic agent.

  本文提供的是新型 sirtuin 调节化合物 (XII) 和 (XIII)。sirtuin调节化合物可用于延长细胞寿命，治疗和/或预防多种疾病和失调，包括与衰老或压力、糖尿病、肥胖症、神经退行性疾病、心血管疾病、凝血障碍、炎症、癌症和/或潮红有关的疾病或失调，以及可从线粒体活性增强中获益的疾病或失调。此外，还提供了由sirtuin调节化合物与另一种治疗剂组合而成的组合物。
• Discovery of oxazolo[4,5-b]pyridines and related heterocyclic analogs as novel SIRT1 activators
  作者：Jean E. Bemis、Chi B. Vu、Roger Xie、Joseph J. Nunes、Pui Yee Ng、Jeremy S. Disch、Jill C. Milne、David P. Carney、Amy V. Lynch、Lei Jin、Jesse J. Smith、Siva Lavu、Andre Iffland、Michael R. Jirousek、Robert B. Perni

  DOI：10.1016/j.bmcl.2008.11.106

  日期：2009.4

  SIRT1 is an NAD(+)-dependent protein deacetylase that appears to produce beneficial effects on metabolic parameters such as glucose and insulin homeostasis. Activation of SIRT1 by resveratrol ( 1) has been shown to modulate insulin resistance, increase mitochondrial content and prolong survival in lower organisms and in mice on a high fat diet. Herein, we describe the identification and SAR of a series of oxazolo[4,5-b]pyridines as novel small molecule activators of SIRT1 which are structurally unrelated to and more potent than resveratrol. (C) 2009 Published by Elsevier Ltd.